Patents by Inventor Lv LIAO

Lv LIAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11530213
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: December 20, 2022
    Assignee: Novartis AG
    Inventors: Guillaume Barbe, Gregory Raymond Bebernitz, Sicong Geng, Hatice Belgin Gulgeze Efthymiou, Lv Liao, Fupeng Ma, Ruowei Mo, David Thomas Parker, Yunshan Peng, Stefan Peukert, Nichola Smith, Ken Yamada, Kayo Yasoshima
  • Publication number: 20210284635
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: October 15, 2020
    Publication date: September 16, 2021
    Inventors: Guillaume BARBE, Gregory Raymond BEBERNITZ, Sicong GENG, Hatice Belgin GULGEZE EFTHYMIOU, Lv LIAO, Fupeng MA, Ruowei MO, David Thomas PARKER, Yunshan PENG, Stefan PEUKERT, Nichola Smith, Ken YAMADA, Kayo YASOSHIMA
  • Publication number: 20210155606
    Abstract: The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: February 8, 2021
    Publication date: May 27, 2021
    Inventors: Luca ARISTA, Sreehari BABU, Jianwei BIAN, Kai CUI, Michael Patrick DILLON, Rene LATTMANN, Jialiang LI, Lv LIAO, Dimitrios LIZOS, Rita RAMOS, Nikolaus Johannes STIEFL, Thomas ULLRICH, Peggy USSELMANN, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Sven WEILER, Yubo ZHANG, Yizong ZHOU, Tingying ZHU
  • Patent number: 10947218
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: March 16, 2021
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Sreehari Babu, Jianwei Bian, Kai Cui, Michael Patrick Dillon, Rene Lattmann, Jialiang Li, Lv Liao, Dimitrios Lizos, Rita Ramos, Nikolaus Johannes Stiefl, Thomas Ullrich, Peggy Usselmann, Xiaoyang Wang, Liladhar Murlidhar Waykole, Sven Weiler, Yubo Zhang, Yizong Zhou, Tingying Zhu
  • Patent number: 10844055
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: November 24, 2020
    Assignee: NOVARTIS AG
    Inventors: Guillaume Barbe, Gregory Raymond Bebernitz, Sicong Geng, Hatice Belgin Gulgeze Efthymiou, Lv Liao, Fupeng Ma, Ruowei Mo, David Thomas Parker, Yunshan Peng, Stefan Peukert, Ken Yamada, Kayo Yasoshima, Nichola Smith
  • Publication number: 20200299265
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: May 27, 2020
    Publication date: September 24, 2020
    Inventors: Luca ARISTA, Sreehari BABU, Jianwei BIAN, Kai CUI, Michael Patrick DILLON, Rene LATTMANN, Jialiang LI, Lv LIAO, Dimitrios LIZOS, Rita RAMOS, Nikolaus Johannes STIEFL, Thomas ULLRICH, Peggy USSELMANN, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Sven WEILER, Yubo ZHANG, Yizong ZHOU, Tingying ZHU
  • Patent number: 10710980
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 14, 2020
    Assignee: Novartis AG
    Inventors: Luca Arista, Sreehari Babu, Jianwei Bian, Kai Cui, Michael Patrick Dillon, Rene Lattmann, Jialiang Li, Lv Liao, Dimitrios Lizos, Rita Ramos, Nikolaus Johannes Stiefl, Thomas Ullrich, Peggy Usselmann, Xiaoyang Wang, Liladhar Murlidhar Waykole, Sven Weiler, Yubo Zhang, Yizong Zhou, Tingying Zhu
  • Patent number: 10507201
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 17, 2019
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Diana Graus Porta, Carolina Haefliger, Bo Han, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Masato Murakami, Pierre Nimsgern, Michael Palmer, Dale Porter, Sebastien Ripoche, Can Wang, Youzhen Wang, Andreas Weiss, Jing Xiong, Xianglin Zhao
  • Patent number: 10463653
    Abstract: The present invention relates to therapeutic uses of compounds of formula (1) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: November 5, 2019
    Assignee: NOVARTIS AG
    Inventors: Lv Liao, Jing Xiong
  • Publication number: 20190263803
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: March 1, 2019
    Publication date: August 29, 2019
    Inventors: Guillaume BARBE, Gregory Raymond BEBERNITZ, Sicong GENG, Hatice Belgin GULGEZE EFTHYMIOU, Lv LIAO, Fupeng MA, Ruowei MO, David Thomas PARKER, Yunshan PENG, Stefan PEUKERT, Ken YAMADA, Kayo YASOSHIMA
  • Publication number: 20190231760
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: February 28, 2019
    Publication date: August 1, 2019
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Diana GRAUS PORTA, Carolina HAEFLIGER, Bo HAN, Thomas KNOPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Masato MURAKAMI, Pierre NIMSGERN, Michael PALMER, Dale PORTER, Sebastien RIPOCHE, Can WANG, Youzhen WANG, Andreas WEISS, Jing XIONG, Xianglin ZHAO
  • Publication number: 20190161474
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: July 18, 2017
    Publication date: May 30, 2019
    Inventors: Luca ARISTA, Sreehari BABU, Jianwei BIAN, Kai CUI, Michael Patrick DILLON, Rene LATTMANN, Jialiang LI, Lv LIAO, Dimitrios LIZOS, Rita RAMOS, Nikolaus Johannes STIEFL, Thomas ULLRICH, Peggy USSELMANN, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Sven WEILER, Yubo ZHANG, Yizong ZHOU, Tingying ZHU
  • Patent number: 10266531
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: April 23, 2019
    Assignee: Novartis AG
    Inventors: Guillaume Barbe, Gregory Raymond Bebernitz, Sicong Geng, Hatice Belgin Gulgeze Efthymiou, Lv Liao, Fupeng Ma, Ruowei Mo, David Thomas Parker, Yunshan Peng, Stefan Peukert, Ken Yamada, Kayo Yasoshima
  • Publication number: 20190076412
    Abstract: The present invention relates to therapeutic uses of compounds of formula (1) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 13, 2018
    Publication date: March 14, 2019
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Thomas KNÖPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Pierre NIMSGERN, Sebastien RIPOCHE, Jing XIONG, Bo HAN, Can WANG, Xianglin ZHAO
  • Patent number: 10130629
    Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: November 20, 2018
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Jorge Garcia Fortanet, Pascal Furet, Diana Graus Porta, Nafeeza Hafeez, Bo Han, Thomas Knoepfel, Matthew J. LaMarche, Catherine Leblanc, Lv Liao, Robert Mah, Dale Porter, Can Wang, Markus Wartmann, Jing Xiong, Xianglin Zhao
  • Publication number: 20180185341
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: October 2, 2015
    Publication date: July 5, 2018
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Diana GRAUS PORTA, Carolina HAEFLIGER, Bo HAN, Thomas KNÖPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Masato MURAKAMI, Pierre NIMSGERN, Michael PALMER, Dale PORTER, Sebastien RIPOCHE, Can WANG, Youzhen WANG, Andreas WEISS, Jing XIONG, Xianglin ZHAO
  • Publication number: 20180111932
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: October 19, 2017
    Publication date: April 26, 2018
    Inventors: Guillaume BARBE, Gregory Raymond BEBERNITZ, Sicong GENG, Hatice Belgin GULGEZE EFTHYMIOU, Lv LIAO, Fupeng MA, Ruowei MO, David Thomas PARKER, Yunshan PENG, Stefan PEUKERT, Ken YAMADA, Kayo YASOSHIMA
  • Patent number: 9896449
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: February 20, 2018
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Pierre Nimsgern, Sebastien Ripoche, Jing Xiong, Bo Han, Can Wang, Xianglin Zhao
  • Patent number: 9802917
    Abstract: The present invention relates to particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, to a process of making said particles, to pharmaceutical compositions comprising said particles and to method of treating cancers using said pharmaceutical compositions.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: October 31, 2017
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Bo Han, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Franck Mallet, Julie Martz, Can Wang, Jing Xiong, Xianglin Zhao
  • Publication number: 20170066766
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Applicant: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Pierre Nimsgern, Sebastien Ripoche, Jing Xiong, Bo Han, Can Wang, Xianglin Zhao